How much revenue does CStone Pharmaceuticals make?

CStone Pharmaceuticals reported 269.58 million CNY in revenue for fiscal year 2025, down 33.8% from 407.21 million CNY in fiscal year 2024.

Where does CStone Pharmaceuticals make most of its revenue?

Outside Mainland China: 69% of revenue by region in fiscal year 2025, followed by Mainland China (31%).

What companies are similar to CStone Pharmaceuticals?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Shanghai Henlius Biotech, Inc. (2696.HK), Keymed Biosciences Inc. (2162.HK), HBM Holdings Limited (2142.HK), Alphamab Oncology (9966.HK).

CStone Pharmaceuticals (2616.HK) Stock

About CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction...

At a glance

CStone Pharmaceuticals reported revenue of 269.58 million CNY for fiscal year 2025, down 33.8% from fiscal year 2024, and net income of -437.00 million CNY. Outside Mainland China was its largest region in fiscal year 2025, with 69% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.